Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Yang, Chenjie ^a   Kim, Seon Hee ^a   Bianco, Nicole R ^a   Robbins, Paul D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; MESSENGER RNA; OVALBUMIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL MATURATION; CELL MIGRATION; CELL TRANSPORT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; EXOSOME; FEMALE; FLOW CYTOMETRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ANIMAL; ANTIGEN PRESENTING CELL; BIOSYNTHESIS; GENETICS; IMMUNOLOGY;

MURINAE;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; EXOSOMES; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-4; MICE; OVALBUMIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960984966     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022517     Document Type: Article

References (57)

1. Pardoll D, (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839.
2. Zou W, (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
3. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V, (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162-179.
4. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S, (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74: 181-273.
5. Thery C, Ostrowski M, Segura E, (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581-593.
6. Clayton A, Mason MD, (2009) Exosomes in tumour immunity. Curr Oncol 16: 46-49.
7. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ, (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113 Pt 19: 3365-3374.
8. Thery C, Zitvogel L, Amigorena S, (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2: 569-579.
9. van Niel G, Porto-Carreiro I, Simoes S, Raposo G, (2006) Exosomes: a common pathway for a specialized function. J Biochem 140: 13-21.
10. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, et al. (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
11. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7: 297-303.
12. Dai S, Wan T, Wang B, Zhou X, Xiu F, et al. (2005) More efficient induction of HLA-A*0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells. Clin Cancer Res 11: 7554-7563.
13. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z, (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67: 7458-7466.
14. Navabi H, Croston D, Hobot J, Clayton A, Zitvogel L, et al. (2005) Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells Mol Dis 35: 149-152.
15. Dai S, Wei D, Wu Z, Zhou X, Wei X, et al. (2008) Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 16: 782-790.
16. Dai S, Zhou X, Wang B, Wang Q, Fu Y, et al. (2006) Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells. J Mol Med 84: 1067-1076.
17. Yang Y, Xiu F, Cai Z, Wang J, Wang Q, et al. (2007) Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells. J Cancer Res Clin Oncol 133: 389-399.
18. Zhang Y, Luo CL, He BC, Zhang JM, Cheng G, et al. (2010) Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. Int J Oncol 36: 133-140.
19. Chen W, Wang J, Shao C, Liu S, Yu Y, et al. (2006) Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 36: 1598-1607.
20. Xiu F, Cai Z, Yang Y, Wang X, Wang J, et al. (2007) Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med 85: 511-521.
21. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, et al. (2008) Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 68: 1228-1235.
22. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL, (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 9: 5113-5119.
23. Taylor DD, Gercel-Taylor C, (2005) Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer 92: 305-311.
24. Clayton A, Tabi Z, (2005) Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis 34: 206-213.
25. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, et al. (2008) Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 180: 7249-7258.
26. Liu C, Yu S, Zinn K, Wang J, Zhang L, et al. (2006) Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 176: 1375-1385.
27. Yu S, Liu C, Su K, Wang J, Liu Y, et al. (2007) Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-6875.
28. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, et al. (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 66: 9290-9298.
29. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL, (2010) Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 5: e11469.
30. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, et al. (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120: 457-471.
31. Keller S, Konig AK, Marme F, Runz S, Wolterink S, et al. (2009) Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 278: 73-81.
32. Peche H, Renaudin K, Beriou G, Merieau E, Amigorena S, et al. (2006) Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant 6: 1541-1550.
33. Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, et al. (2001) "Tolerosomes" are produced by intestinal epithelial cells. Eur J Immunol 31: 2892-2900.
34. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD, (2007) MHC class II+ exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J Immunol 179: 2235-2241.
35. Ostman S, Taube M, Telemo E, (2005) Tolerosome-induced oral tolerance is MHC dependent. Immunology 116: 464-476.
36. Prado N, Marazuela EG, Segura E, Fernandez-Garcia H, Villalba M, et al. (2008) Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction. J Immunol 181: 1519-1525.
37. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, et al. (1998) Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 95: 4613-4618.
38. Lechman ER, Jaffurs D, Ghivizzani SC, Gambotto A, Kovesdi I, et al. (1999) Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. J Immunol 163: 2202-2208.
39. Kim SH, Evans CH, Kim S, Oligino T, Ghivizzani SC, et al. (2000) Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res 2: 293-302.
40. Lechman ER, Keravala A, Nash J, Kim SH, Mi Z, et al. (2003) The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen. Gene Ther 10: 2029-2035.
41. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, et al. (1998) NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 95: 13859-13864.
42. Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, et al. (2006) Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther 13: 289-300.
43. Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD, (2007) Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J Immunol 179: 2242-2249.
44. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, et al. (2005) Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 174: 6440-6448.
45. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, et al. (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149-5153.
46. Meade R, Askenase PW, Geba GP, Neddermann K, Jacoby RO, et al. (1992) Transforming growth factor-beta 1 inhibits murine immediate and delayed type hypersensitivity. J Immunol 149: 521-528.
47. D'Orazio TJ, Niederkorn JY, (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160: 2089-2098.
48. Jacysyn JF, Abrahamsohn IA, Macedo MS, (2003) IL-4 from Th2-type cells suppresses induction of delayed-type hypersensitivity elicited shortly after immunization. Immunol Cell Biol 81: 424-430.
49. Seder RA, Marth T, Sieve MC, Strober W, Letterio JJ, et al. (1998) Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. J Immunol 160: 5719-5728.
50. Cone RE, Li X, Sharafieh R, O'Rourke J, Vella AT, (2007) The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma. Immunology 120: 112-119.
51. Rock KL, Clark K, (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156: 3721-3726.
52. Mallegol J, Van Niel G, Lebreton C, Lepelletier Y, Candalh C, et al. (2007) T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. Gastroenterology 132: 1866-1876.
53. Hood JL, San RS, Wickline SA, (2011) Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 71: 3792-3801.
54. Whalen JD, Thomson AW, Lu L, Robbins PD, Evans CH, (2001) Viral IL-10 gene transfer inhibits DTH responses to soluble antigens: evidence for involvement of genetically modified dendritic cells and macrophages. Mol Ther 4: 543-550.
55. Sack U, Gunther A, Pfeiffer R, Genest M, Kinne J, et al. (1999) Systemic characteristics of chronic arthritis induced by transfer of human rheumatoid synovial membrane into SCID mice (human/murine SCID arthritis). J Autoimmun 13: 335-346.
56. Moore MW, Carbone FR, Bevan MJ, (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54: 777-785.
57. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL, (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1: 649-653.